Aviragen Therapeutics (AVIR) Stock Price Down 7.5%

Aviragen Therapeutics Inc (NASDAQ:AVIR) shares traded down 7.5% during mid-day trading on Monday . The stock traded as low as $0.57 and last traded at $0.62. 728,619 shares changed hands during mid-day trading, an increase of 12% from the average session volume of 648,693 shares. The stock had previously closed at $0.67.

Separately, HC Wainwright reaffirmed a “hold” rating on shares of Aviragen Therapeutics in a research note on Monday, November 6th.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.63 and a current ratio of 6.63. The firm has a market cap of $24.24, a P/E ratio of -0.98 and a beta of -0.09.

Aviragen Therapeutics (NASDAQ:AVIR) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). Aviragen Therapeutics had a negative return on equity of 114.15% and a negative net margin of 277.53%. equities analysts anticipate that Aviragen Therapeutics Inc will post -0.96 EPS for the current year.

A hedge fund recently raised its stake in Aviragen Therapeutics stock. FMR LLC raised its position in shares of Aviragen Therapeutics Inc (NASDAQ:AVIR) by 0.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,005,345 shares of the biotechnology company’s stock after purchasing an additional 2,845 shares during the quarter. FMR LLC owned approximately 2.60% of Aviragen Therapeutics worth $673,000 at the end of the most recent quarter. Institutional investors and hedge funds own 25.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/01/24/aviragen-therapeutics-avir-stock-price-down-7-5.html.

About Aviragen Therapeutics

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.

Receive News & Ratings for Aviragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply